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Abstract
Background: The increased use of meta-analysis in systematic reviews of healthcare interventions has highlighted several
types of bias that can arise during the completion of a randomised controlled trial. Study publication bias and outcome
reporting bias have been recognised as a potential threat to the validity of meta-analysis and can make the readily available
evidence unreliable for decision making.
Methodology/Principal Findings: In this update, we review and summarise the evidence from cohort studies that have
assessed study publication bias or outcome reporting bias in randomised controlled trials. Twenty studies were eligible of
which four were newly identified in this update. Only two followed the cohort all the way through from protocol approval
to information regarding publication of outcomes. Fifteen of the studies investigated study publication bias and five
investigated outcome reporting bias. Three studies have found that statistically significant outcomes had a higher odds of
being fully reported compared to non-significant outcomes (range of odds ratios: 2.2 to 4.7). In comparing trial publications
to protocols, we found that 40–62% of studies had at least one primary outcome that was changed, introduced, or omitted.
We decided not to undertake meta-analysis due to the differences between studies.
Conclusions: This update does not change the conclusions of the review in which 16 studies were included. Direct empirical
evidence for the existence of study publication bias and outcome reporting bias is shown. There is strong evidence of an
association between significant results and publication; studies that report positive or significant results are more likely to
be published and outcomes that are statistically significant have higher odds of being fully reported. Publications have been
found to be inconsistent with their protocols. Researchers need to be aware of the problems of both types of bias and
efforts should be concentrated on improving the reporting of trials.
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Introduction
Study publication bias arises when studies are published or not
depending on their results; it has received much attention [1,2].
Empirical research consistently suggests that published work is
more likely to be positive or statistically significant (P,0.05) than
unpublished research [3]. Study publication bias will lead to
overestimation of treatment effects; it has been recognised as a
threat to the validity of meta-analysis and can make the readily
available evidence unreliable for decision making. There is
additional evidence that research without statistically significant
results takes longer to achieve publication than research with
significant results, further biasing evidence over time [4–7]. This
‘‘time lag bias’’ (or ‘‘pipeline bias’’) will tend to add to the bias
since results from early available evidence tend to be inflated and
exaggerated [8,9].
Within-study selective reporting bias relates to studies that have
been published. It has been defined as the selection on the basis of
the results of a subset of the original variables recorded for
inclusion in a publication [10]. Several different types of selective
reporting within a study may occur. For example, selective
reporting of analyses may include intention-to–treat analyses
versus per–protocol analyses, endpoint score versus change from
baseline, different time points or subgroups [11]. Here we focus on
the selective reporting of outcomes from those that were originally
measured within a study; outcome reporting bias (ORB).
Randomised controlled trials (RCTs) are planned experiments,
involving the random assignment of participants to interventions,
and are seen as the gold standard of study designs to evaluate the
effectiveness of a treatment in medical research in humans [12].
The likely bias from selective outcome reporting is to overestimate
the effect of the experimental treatment.
The original version of this systematic review [13] summarised
the empirical evidence for the existence of study publication bias
and outcome reporting bias. It found that 12 of the 16 included
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empirical studies demonstrated consistent evidence of an associ-
ation between positive or statistically significant results and
publication and that statistically significant outcomes have higher
odds of being fully reported.
The ORBIT (Outcome Reporting Bias In Trials) study
conducted by authors of this review, found that a third of
Cochrane reviews found at least one trial with high suspicion of
outcome reporting bias for a single review primary outcome [14].
Work has also been published to show how to identify outcome
reporting bias within a review and relevant trial reports [15].
Studies comparing trial publications to protocols or trial
registries are also accumulating evidence on the proportion of
studies in which at least one primary outcome was changed,
introduced, or omitted [16].
Thus, the bias from missing outcome data that may affect a
meta-analysis is on two levels: non-publication due to lack of
submission or rejection of study reports (a study level problem) and
the selective non-reporting of outcomes within published studies
on the basis of the results (an outcome level problem). While much
effort has been invested in trying to identify the former [1,2], it is
equally important to understand the nature and frequency of
missing data from the latter level.
The aim of this study was to update the original review [13] and
summarise the evidence from empirical cohort studies that have
assessed study publication bias and/or outcome reporting bias in
RCTs approved by a specific ethics committee or other inception
cohorts of RCTs.
Methods
Study Inclusion Criteria
We included research that assessed an inception cohort of
RCTs for study publication bias and/or outcome reporting bias.
We focussed on inception cohorts with study protocols being
registered before the start of the study as this type of prospective
design were deemed more reliable. We excluded cohorts based on
prevalence archives, in which a protocol is registered after a study
is launched or completed, since such cohorts can already be
affected by publication and selection bias.
Both cohorts containing exclusively RCTs or containing a mix
of RCTs and non-RCTs were eligible. For those studies where it
was not possible to identify the study type (i.e. whether any
included studies were RCTs), we attempted to contact the authors
to try to resolve this. In cases where it could not be resolved,
studies were excluded. Those studies containing exclusively non-
RCTs were excluded.
The assessment of RCTs in the included studies had to involve
comparison of the protocol against all publications (for outcome
reporting bias) or information from trialists (for study publication
bias).
Search Strategy
The search strategy from the original version of this review [13]
was used in this update. In the original review, screening of titles
was carried out by one author (KD), but in this update two authors
(KD and JJK) screened both titles and abstracts. No masking was
used during the screening of abstracts. MEDLINE (1946 to 2012),
SCOPUS (1960 to 2012) and the Cochrane Methodology Register
(1898 to 2012) were searched without language restrictions (see
Appendix S1 for all search strategies). SCOPUS is a much larger
database than EMBASE, it offers more coverage of scientific,
technical, medical and social science literature than any other
database. Over 90% of the sources indexed by EMBASE are also
indexed by SCOPUS plus many other indexed sources as well.
Additional steps were taken to complement electronic database
searches:the lead or contact authors of all identified studies were
asked to identify further studies and references of included studies
were checked for further eligible studies.
Quality Assessment
To assess the methodological quality of the included studies, the
same criteria was applied as in the original version of this review
[13].
1. Was there an inception cohort?
Yes = a sample of clinical trials registered at onset or on a roster
(e.g. approved by an ethics committee) during a specified period of
time.
No = anything else.
Unclear.
2. Was there complete follow up (after data-analysis) of all the
trials in the cohort?
Yes $90%.
No ,90%.
Unclear.
3. Was publication ascertained through personal contact with
the investigators?
Yes = personal contact with investigators, or searching the
literature and personal contact with the investigator.
No = searching the literature only.
Unclear.
4. Were positive and negative findings clearly defined?
Yes = clearly defined.
No = not clearly defined.
Unclear.
5. Were protocols compared to publications?
Yes = protocols were compared to publications.
No = protocols were not considered in the study.
Unclear.
Data Extraction
A flow diagram (Figure 1, text S1) to show the status of
approved protocols was completed for each empirical study by the
first author only (KD) in the original version of the review and by
two authors in the update (KD and JJK) using information
available in the publication or further publications. Disagreements
were resolved through discussion. Lead or contact authors of the
empirical studies were then contacted by email and sent the flow
diagram for their study to check the extracted data along with
requests for further information or clarification of definitions if
required. No masking was used and disagreements were resolved
through discussion between KD and the lead or contact author of
the empirical studies. Where comments from the original author
were not available, PRW reviewed the report and discussed
queries with KD in the original version of the review.
Characteristics of the cohorts were extracted by the first author
in the original version of the review for each empirical study and
issues relating to the methodological quality of the study were
noted. This process was undertaken by two authors (JJK and KD)
for newly identified studies in the update of this review. We
recorded the definitions of ‘published’ employed in each empirical
study. Further, we looked at the way the significance of the results
of the studies in each cohort were investigated (i.e. direction of
results and whether the study considered a p-value #0.05 as
definition of significance and where there were no statistical tests
whether the results were categorised as negative, positive,
important or unimportant). We extracted data on the number of
positive and negative trials that were published in each cohort and
we extracted all information on the main objectives of each
Study Publication Bias and Outcome Reporting Bias
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empirical study and separated these according to whether they
related to study level or outcome level bias.
Data Analysis
This review provides a descriptive summary of the included
empirical studies. We refrained from statistically combining results
from the different cohorts due to the differences in their design.
Results
Search Results
The search of MEDLINE, SCOPUS and the Cochrane
Methodology Register led to 2525, 2090 and 832 references,
respectively. Titles were checked by the two authors (KD and JJK)
in this update and abstracts obtained for 86 potentially relevant
studies. Abstracts were assessed for eligibility by both authors; 40
Figure 1. Study flow diagram.
doi:10.1371/journal.pone.0066844.g001
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were excluded and full papers were obtained when available for
46.
Nineteen empirical studies were deemed eligible [3–5,7,17–31],
sixteen of which were included in the original version of this review
[13].
References from the included empirical studies led to another
eligible study [32].
Thus in total, the search strategy identified 20 eligible empirical
studies (Figure 2), of which, four were newly included in this
update [21,28,31,32]. Two studies that should have been in the
original review were included in this review. One study [28] was
missed as a result of single author study selection in the original
review and a second study [32] was identified through a reference
search of a newly identified study [21]. All previously identified
studies were found again.
Two further studies are ongoing [33,34].
Excluded Studies
Twenty five studies were excluded; eight were not inception
cohorts [35–42]; in two studies, the authors of included RCTs
were not contacted for information on publication [43,44]; in six,
only published studies were included in the cohort [45–50]; in six
studies, trial registries were investigated and were not considered
as inception cohorts [51–56]; in one we could not confirm if any of
the included studies were RCTs [57]; the author of a letter
confirmed the study mentioned never began [58] and in a further
study [59] was an analysis on oral presentations from one of the
included studies [7].
Included Studies
Study publication bias. Fifteen empirical studies considered
the process up to the point of publication [3–5,7,19–24,27,28,30–
32]. However, six of these empirical studies [20,21,27,28,31,32]
did not consider whether a study was submitted for publication.
Five cohorts included only RCTs [3,5,27,28,30]; in the
remaining ten cohorts [4,7,19–24,31,32] the proportion of
included RCTs ranged from 14% to 56%. The results presented
in the flow diagrams relate to all studies within each cohort
because it was not possible to separate information for different
types of studies (RCTs versus other).
Outcome reporting bias. Five empirical studies covered the
entire process from the study protocol to the publication of study
outcomes [17,18,25,26,29]. However, three of these empirical
studies [25,26,29] did not consider whether a study was submitted
for publication. Four cohorts included only RCTs [17,18,25,29];
in the remaining cohort [26] the proportion of included RCTs was
13%.
Two studies are currently being updated and data on outcomes
is being analysed for publication [29,31].
Study Characteristics
Table 1 contains information on empirical study characteristics.
The majority of the empirical study objectives related to study
publication bias and publication rates or outcome reporting bias.
Study publication bias. Four of the empirical studies
investigating study publication bias also assessed time lag bias
[4,5,7,32], four [21,27,28,31] assessed the outcome of protocols
submitted to a research ethics committee (for example whether
trials were started and if they were published) and another
considered whether absence of acknowledged funding hampered
implementation or publication [22]. Eleven of the empirical
studies [4,7,19,21–24,27,28,31,32] assessed protocols approved by
ethics committees, one [3] assessed those approved by health
institutes, one assessed trials processed through a hospital
pharmacy [30], one assessed studies funded by the NHS and
commissioned by the North Thames Regional Office [20] and one
empirical study [5] assessed trials conducted by NIH-funded
clinical trials groups. The time period between protocol approval
and assessment of publication status varied widely (less than one
year to 34 years).
Outcome reporting bias. Four of the empirical studies
[17,25,26,29] assessed protocols approved by ethics committees
and one empirical study [18] assessed those approved by a health
institute. The time period between protocol approval and
assessment of publication status varied from four to eight years.
Quality Assessment
Details of the methodological quality are presented in Table 2.
The overall methodological quality of included empirical studies
was good, with more than half of studies meeting all criteria.
Study publication bias. Seven of the fifteen empirical
studies [5,7,27,28,30–32] met all four of the criteria for studies
investigating study publication bias (inception cohort, complete
follow up of all trials, publication ascertained through personal
contact with the investigator and definition of positive and
negative findings clearly defined). In six empirical studies
[3,4,7,21,22,24] there was less than 90% follow up of trials and
in two empirical studies [19,20] the definition of positive and
negative findings was unclear.
Outcome reporting bias. All five empirical studies
[17,18,25,26,29] met all five criteria for studies investigating
ORB (inception cohort, complete follow up of all trials,
publication ascertained through personal contact with the
investigator, definition of positive and negative findings clearly
defined and comparison of protocol to publication).
As some studies may have several specified primary outcomes
and others none, we looked at how each of the empirical studies
dealt with this: Hahn et al [26] looked at the consistency between
protocols and published reports in regard to the primary outcome
and it was only stated that there were two primary outcomes in
one study. In both of their empirical studies Chan et al [17,18]
distinguished harm and efficacy outcomes but did consider the
consistency of primary outcomes between protocols and publica-
tions and stated how many had more than one primary outcome.
Ghersi et al [25] included studies with more than one primary
outcome and included all primary outcomes in the analysis but
excluded studies with primary outcomes that were non identifiable
or included more than two time points. This is due to complex
outcomes being more prone to selective reporting. von Elm et al
[29] considered harm and efficacy outcomes and primary
outcomes.
Flow Diagrams
The flow diagrams (Figures 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22) show the status of approved
protocols in included empirical studies based on available
publications and additional information obtained such as number
of studies stopped early or never started.
Study publication bias. No information other than the
study report was available for one empirical study [24] due to its
age. Information could not be located for four empirical studies
[3,19,23,28]. A conference abstract and poster was only available
for one empirical study presented over 10 years ago [30]. Extra
information from lead or contact authors was available for nine
empirical studies [4,5,7,20–22,27,31,32], including data to com-
plete flow diagrams, information on definitions and clarifications.
Outcome reporting bias. Extra information from lead or
contact authors was available for four empirical studies
Study Publication Bias and Outcome Reporting Bias
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Figure 2. PRISMA flow diagram.
doi:10.1371/journal.pone.0066844.g002
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[17,18,26,29], including data to complete flow diagrams, infor-
mation on definitions, clarifications and extra information on
outcomes. Original flow diagrams and questions asked are
available on request.
Figure 3 shows for illustrative purposes the completed flow
diagram for the empirical study conducted by Chan et al [17] on
the status of 304 protocols approved by the Scientific-Ethical
Committees for Copenhagen and Frederiksberg in 1994–1995.
The empirical study was conducted in 2003, which allowed
sufficient time for trial completion and publication. Thirty studies
were excluded as the files were not found. Surveys were sent to
trial investigators with a response rate of 151 out of 274 (55%); of
these two were ongoing, 38 had stopped early, 24 studies had
never started and 87 studies were completed. Information from the
survey responses (151) and the literature search alone (123)
indicated that 120 studies had been submitted for publication and
154 studies had not been submitted for publication. Of the 120
submitted studies; 102 had been fully published, 16 had been
submitted or were under preparation and two had not been
accepted for publication. This resulted in 156 studies not being
published.
Publication and Trial Findings
Study publication bias. Table 3 shows the total number of
studies published in each cohort which varies widely from 21% to
93%. Nine of the cohorts [3–5,7,19,22–24,30] consider what
proportion of trials with positive and negative results are
published, ranging from 60% to 98% and from 19% to 85%,
respectively. Only four cohorts [4,7,19,24] consider what percent-
age of studies with null results (no difference observed between the
two study groups, p.0.10, inconclusive) are published (32% to
44%). The results consistently show that positive studies are more
likely to be published compared to negative studies.
Table 4 shows general consistency in the definition of
‘published.’ However, two empirical studies [3,23] considered
grey literature in their definition of ‘published’ although informa-
tion on full publications and grey literature publications are
separated (Figures 5, 6). Although not considered in the definition
of ‘published’, seven empirical studies [7,21,22,24,27,28,32] gave
information on the grey literature or reports in preparation. Three
empirical studies gave no information on their definition of
‘published’ [19,20,30]. In addition, results are presented for the
percentage of studies not submitted for journal publication (7% to
58%), of studies submitted but not accepted for publication (0 to
20%) by the time of analysis of the cohort and the percentage of
studies not published that were not submitted (63% to 100%). This
implies that studies remain unpublished due largely to failure to
submit rather than rejection by journals.
The main findings of the empirical studies are shown in Table 5
and they are separated into study level and outcome level results.
Nine of the included cohort studies [3,4,7,19,20,23,24,30,32]
investigated results in relation to their statistical significance. One
empirical study considered the importance of the results as rated
by the investigator [22] and another empirical study considered
confirmatory versus inconclusive results [7]. Five of the empirical
studies [3,4,7,23,24] that examined the association between
publication and statistical significance found that studies with
statistically significant results were more likely to be published than
those with non-significant results. Stern et al [4] reported that this
finding was even stronger for their subgroup of clinical trials
(Hazard Ratio (HR) 3.13 (95% confidence interval (CI) 1.76,
5.58), p= 0.0001) compared to all quantitative studies (HR 2.32
(95% CI 1.47, 3.66), p= 0.0003). One empirical study [19] found
that studies with statistically significant results were more likely to
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Figure 3. Status of approved protocols for Chan 2004b study [17].
doi:10.1371/journal.pone.0066844.g003
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be submitted for publication than those with non-significant
results. Easterbrook et al [24] also found that study publication
bias was greater with observational and laboratory-based exper-
imental studies (Odds Ratio (OR) 3.79, 95% CI; 1.47, 9.76) than
with RCTs (OR 0.84, 95% CI; 0.34, 2.09). Hall et al [32] found
no difference in publication success in high impact journals i.e.,
.5 for trials reporting statistically significant or non-significant
results (RR 0.929; 95% CI 0.759–1.137; P= 0.537). However, two
empirical studies [20,30] found no statistically significant evidence
for study publication bias (RR 4 (95% CI 0.6, 32) p= 0.1 and OR
0.53 (95% CI 0.25, 1.1) p= 0.1).
Ioannidis et al [5] found that positive trials were submitted for
publication more rapidly after completion than negative trials
(median 1 vs 1.6 years, p,0.001) and were published more rapidly
Figure 4. Status of approved protocols for Easterbrook 1991 study [24].
doi:10.1371/journal.pone.0066844.g004
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after submission (median 0.8 vs 1.1 years, p,0.04). Stern el al [4]
and Decullier et al [7] also considered time to publication and
found that those studies with positive results were published faster
than those with negative results (median 4.8 v 8.0 years [4] and
HR 2.48 (95% CI 1.36, 4.55) [7], respectively). However, for 53
trials where data were available, Hall et al [32] also found that
there was no difference in the time to publication for trials
reporting statistically significant results vs those reporting non-
Figure 5. Status of approved protocols for Dickersin 1992 study [23].
doi:10.1371/journal.pone.0066844.g005
Study Publication Bias and Outcome Reporting Bias
PLOS ONE | www.plosone.org 13 July 2013 | Volume 8 | Issue 7 | e66844
significant results (32616 vs 36624 months; mean 6 SD;
P= 0.869).
Pich et al [27] looked at whether studies in their cohort were
completed and published; 64% (92/143) of initiated trials were
finished in accordance with the protocol and 31% (38/123) were
published (or in-press) in peer reviewed journals. The main
objective of the study by Blumle et al [31] was to consider how
eligibility criteria stated in protocols was reported in subsequent
reports, in doing so they noted that 52% of studies in their cohort
were published, decreasing to 48% for RCTs only. Turer et al
Figure 6. Status of approved protocols for Dickersin 1993 study [3].
doi:10.1371/journal.pone.0066844.g006
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Figure 7. Status of approved protocols for Stern 1997 study [4].
doi:10.1371/journal.pone.0066844.g007
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Figure 8. Status of approved protocols for Cooper 1997 study [19].
doi:10.1371/journal.pone.0066844.g008
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Figure 9. Status of trials for Wormald 1997 study [30].
doi:10.1371/journal.pone.0066844.g009
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Figure 10. Status of approved protocols for Ioannidis 1998 study [5].
doi:10.1371/journal.pone.0066844.g010
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Figure 11. Status of approved protocols for Pich 2003 study [27].
doi:10.1371/journal.pone.0066844.g011
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Figure 12. Status of approved protocols for Cronin 2004 study [20].
doi:10.1371/journal.pone.0066844.g012
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Figure 13. Status of approved protocols for Decullier 2005 study [7].
doi:10.1371/journal.pone.0066844.g013
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Figure 14. Status of approved protocols for Decullier 2006 study [22].
doi:10.1371/journal.pone.0066844.g014
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[28] looked at publication rates and found that 47% of studies in
their cohort had been published. de Jong et al [21] aimed to
identify prognostic indicators of the publication rate of clinical
studies and found that 29% of studies had been published,
although some had only been approved 6 months previously.
Seven empirical studies [3,7,19,22–24,30] described reasons
why a study was not published as reported by the trialists. Reasons
related to trial results included: unimportant/null results; results
not interesting; results not statistically significant.
Outcome reporting bias. The total number of studies
published in each cohort varied from 37% to 67% (Table 3).
However, none of the empirical studies investigating ORB
considered the proportions of published trials with positive,
negative, or null overall results.
Table 4 shows that three of the empirical studies [17,18,29]
defined ‘published’ as a journal article; one empirical study [26]
considered grey literature in their definition of ‘published’
although information on full publications and grey literature
Figure 15. Status of approved protocols for Hahn 2002 study [26].
doi:10.1371/journal.pone.0066844.g015
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Figure 16. Status of approved protocols for Chan 2004a study [18].
doi:10.1371/journal.pone.0066844.g016
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Figure 17. Status of approved protocols for Ghersi 2006 study [25].
doi:10.1371/journal.pone.0066844.g017
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Figure 18. Status of approved protocols for von Elm 2008 study [29].
doi:10.1371/journal.pone.0066844.g018
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Figure 19. Status of approved protocols for Turer 2007 study [28].
doi:10.1371/journal.pone.0066844.g019
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Figure 20. Status of approved protocols for De Jong 2010 study [21].
doi:10.1371/journal.pone.0066844.g020
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Figure 21. Status of approved protocols for Blumle 2008 study [31].
doi:10.1371/journal.pone.0066844.g021
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Figure 22. Status of approved protocols for Hall 2007 study [32].
doi:10.1371/journal.pone.0066844.g022
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publications are separated (Figure 15). Although not considered in
the definition of ‘published’, one empirical study [18] gave
information on the grey literature or reports in preparation. Only
two empirical studies [17,18] present results for the percentage of
studies not submitted (31% to 56%), the percentage of studies
submitted but not accepted (1 to 2%) by the time of analysis of the
cohort and the percentage of studies not published that were not
submitted (97% to 99%).
All four empirical studies [17,18,25,29] that examined the
association between outcome reporting bias (outcome level bias)
and statistical significance found that statistically significant
outcomes were more likely to be completely reported than non-
significant outcomes (range of odds ratios: 2.2 to 4.7 (Table 5)).
Five empirical studies [17,18,25,26,29] compared the protocol
and the publication with respect to the primary outcome (Table 5).
Only two empirical studies looked at the different types of
discrepancies that can arise [17,18] and concluded that 40–62% of
trials had major discrepancies between the primary outcomes
specified in protocols and those defined in the published articles.
Four of the included empirical studies found that in 47–74% of
studies the primary outcome stated in the protocol was the same as
in the publication; between 13 and 31% of primary outcomes
specified in the protocol were omitted in the publication and
between 10 and 18% of reports introduced a primary outcome in
the publication that was not specified in the protocol.
Chan et al also looked at efficacy and harm outcomes and in
their Canadian empirical study [18] found that a median of 31%
of efficacy outcomes and 59% of harm outcomes were incom-
pletely reported and statistically significant efficacy outcomes had
a higher odds than non significant efficacy outcomes of being fully
reported (OR 2.7; 95% CI 1.5, 5). In their Danish empirical study
[17] they found that 50% of efficacy and 65% of harm outcomes
per trial were incompletely reported and statistically significant
outcomes had a higher odds of being fully reported compared with
non significant outcomes for both efficacy (OR 2.4, 95% CI; 1.4,
4) and harm (OR 4.7, 95% CI; 1.8, 12) data.
von Elm et al [29] considered efficacy and harm outcomes as
well as primary outcomes overall and found that 32% (223/687)
were reported in the publication but not specified in the protocol
and 42% (227/546) were specified in the protocol but not
reported, however this is preliminary data.
Two empirical studies [17,18] describe the reasons why
outcomes do not get reported but the study is published, these
include lack of clinical importance and lack of statistical
significance.
Discussion
The four newly identified empirical studies only examined study
publication bias. Outcome reporting bias was considered in one of
the cohorts but results have only just been submitted for
publication [31].
Very few of the 20 empirical studies examined both study
publication bias and outcome reporting bias in the same cohort.
Twelve of the included empirical studies demonstrate consistent
evidence of an association between positive or statistically
significant results and publication. They suggest that studies
reporting positive/statistically significant results are more likely to
be published and that statistically significant outcomes have higher
odds of being fully reported.
Table 3. Publication and trial findings.
Study ID Total published (percentage) Positive (percentage) Negative (percentage) Null (percentage)
Easterbrook, 1991 [24] 138/285 (48%) 93/154 (60%) 12/34 (35%) 33/97 (34%)
Dickersin, 1992 [23] 390/514 (76%) 260/314 (83%) 130/200 (65%) NI
Dickersin, 1993 [3] 184/198 (93%) 121/124 (98%) 63/74 (85%) NI
Stern, 1997 [4] 189/321 (59%) 153/232 (66%) 13/37 (35%) 23/52 (44%)
Cooper, 1997 [19] 38/121 (status known for 117/121) (31%) - - -
Wormald, [30] 30/61 (status known for 39 completed trials) (49%) 14/15 (93%) 15/21 (71%) NI
Ioannidis, 1998 [5] 36/66 (55%) 20/27 (74%) 16/39 (41%) NI
Pich, 2003 [27] 26/123 (21%) NI NI NI
Cronin, 2004 [20] 28/70 (40%) NI NI NI
Decullier, 2005 [7] 205/649 (32%) (status known for 2481) 129/188 (67%) 3/16 (19%) 14/44 (32%)
Decullier, 2006 [22] 48/93 (status known for 47/51 completed trials) (52%) 26/37 (70%) 6/10 (60%) NI
Hahn, 2002 [26] 18/27 (67%) NI NI NI
Chan, 2004a [18] 48/105 (46%) NI NI NI
Chan, 2004b [17] 102/274 (37%) NI NI NI
Ghersi, 2006 [25] 103/226 (46%) NI NI NI
Von Elm, 2008 [29] 233/451 (52%) NI NI NI
Turer 2007 [28] 101/217 (47%) NI NI NI
De jong 2010 [21] 22/80 (28%) NI NI NI
Blumle 2008 [31] RCTs: 54/103 (52%); Overall: 109/225 (48%) NI NI NI
Hall 2007 [32] RCTs: 55/89 (62%); Overall: 84/185 (45%) 71/84 (85%) 13/84 (15%) NI
1. Analysis restricted to 248 completed, non confidential, with hypothesis tests and direction of results.
NI No information, this study does not look at this.
2 Not able to work out values.
Status implies positive or negative findings.
doi:10.1371/journal.pone.0066844.t003
Study Publication Bias and Outcome Reporting Bias
PLOS ONE | www.plosone.org 31 July 2013 | Volume 8 | Issue 7 | e66844
T
a
b
le
4
.
A
sp
e
ct
s
o
f
st
u
d
y
le
ve
l
p
u
b
lic
at
io
n
b
ia
s.
S
tu
d
y
D
e
fi
n
it
io
n
o
f
p
u
b
li
sh
e
d
a
rt
ic
le
e
m
p
lo
y
e
d
b
y
e
li
g
ib
le
st
u
d
ie
s
T
im
e
si
n
ce
p
ro
to
co
l
a
p
p
ro
v
e
d
%
N
o
t
su
b
m
it
te
d
1
(9
5
%
C
I)
%
S
u
b
m
it
te
d
b
u
t
n
o
t
a
cc
e
p
te
d
2
(9
5
%
C
I)
%
S
tu
d
ie
s
n
o
t
p
u
b
li
sh
e
d
th
a
t
w
e
re
n
o
t
su
b
m
it
te
d
(9
5
%
C
I)
Ea
st
e
rb
ro
o
k,
1
9
9
1
[2
4
]
A
cc
e
p
ta
n
ce
b
y
a
jo
u
rn
al
(p
u
b
lis
h
e
d
o
r
in
p
re
ss
),
b
u
t
n
o
t
b
o
o
k
ch
ap
te
rs
o
r
p
u
b
lis
h
e
d
m
e
e
ti
n
g
ab
st
ra
ct
s
o
r
p
ro
ce
e
d
in
g
s.
3
ye
ar
s
9
(6
,
1
2
)
6
(3
,
9
)
6
3
(4
9
,
7
7
)
D
ic
ke
rs
in
,
1
9
9
2
[2
3
]
R
e
p
o
rt
e
d
in
o
n
e
o
r
m
o
re
jo
u
rn
al
ar
ti
cl
e
s,
m
o
n
o
g
ra
p
h
s,
b
o
o
ks
,
o
r
ch
ap
te
rs
in
b
o
o
ks
,
w
e
re
av
ai
la
b
le
fr
o
m
m
e
d
ic
al
lib
ra
ri
e
s
o
r
w
e
re
in
d
o
cu
m
e
n
ts
av
ai
la
b
le
fr
o
m
a
p
u
b
lis
h
e
d
ar
ch
iv
e
,
e
.g
.,
th
e
N
at
io
n
al
T
e
ch
n
ic
al
In
fo
rm
at
io
n
se
rv
ic
e
8
ye
ar
s
2
3
(1
9
,
2
7
)
1
.5
(0
,
3
)
9
5
(9
1
,
9
9
)
D
ic
ke
rs
in
,
1
9
9
3
[3
]
A
b
st
ra
ct
s,
jo
u
rn
al
ar
ti
cl
e
s,
b
o
o
k
ch
ap
te
rs
,
p
ro
ce
e
d
in
g
s,
le
tt
e
r
to
th
e
e
d
it
o
r,
o
r
o
th
e
r
m
at
e
ri
al
.
9
ye
ar
s
7
(3
,
1
1
)
0
1
0
0
St
e
rn
,
1
9
9
7
3
[4
]
A
s
an
ar
ti
cl
e
in
a
p
e
e
r
re
vi
e
w
e
d
jo
u
rn
al
4
p
lu
s
ye
ar
s
3
3
(2
8
,
3
8
)
1
3
(8
,1
7
)
8
0
(7
3
,
8
7
)
C
o
o
p
e
r,
1
9
9
7
[1
9
]
N
I
N
I
N
I
W
o
rm
al
d
,
1
9
9
7
[3
0
]
N
I
2
to
3
4
ye
ar
s
2
1
(8
,3
4
)
0
1
0
0
Io
an
n
id
is
,
1
9
9
8
[5
]
P
e
e
r-
re
vi
e
w
e
d
jo
u
rn
al
ar
ti
cl
e
s
1
2
%
co
m
p
le
te
d
le
ss
th
an
1
ye
ar
ag
o
,
2
0
%
co
m
p
le
te
d
o
ve
r
1
ye
ar
ag
o
.
3
2
(2
1
,
4
3
)
2
0
(8
,
3
2
)
7
0
(5
4
,
8
6
)
P
ic
h
,
2
0
0
3
[2
7
]
P
e
e
r
re
vi
e
w
e
d
jo
u
rn
al
ar
ti
cl
e
s
3
ye
ar
s
*
C
ro
n
in
,
2
0
0
4
[2
0
]
N
I
1
to
5
ye
ar
s
*
D
e
cu
lli
e
r,
2
0
0
5
3
[7
]
P
u
b
lis
h
e
d
as
a
sc
ie
n
ti
fi
c
p
ap
e
r.
G
re
y
lit
e
ra
tu
re
–
p
u
b
lis
h
e
d
in
o
th
e
r
fo
rm
at
s
th
an
sc
ie
n
ti
fi
c
p
ap
e
rs
,
th
at
is
g
e
n
e
ra
lly
n
o
t
ac
ce
ss
ib
le
th
ro
u
g
h
lib
ra
ri
e
s
(i
n
te
rn
al
re
p
o
rt
s,
th
e
se
s,
ab
st
ra
ct
s,
p
o
st
e
rs
)
6
ye
ar
s
(2
%
n
o
t
re
ad
y)
5
8
(5
4
,6
2
)
2
(0
,
4
)
9
9
(9
8
,
1
0
0
)
D
e
cu
lli
e
r,
2
0
0
6
3
[2
2
]
P
u
b
lis
h
e
d
as
a
sc
ie
n
ti
fi
c
p
ap
e
r
6
ye
ar
s
4
7
(3
7
,5
7
)
2
(0
,
6
)
9
8
(9
5
,
1
0
0
)
H
ah
n
,
2
0
0
2
[2
6
]
P
u
b
lis
h
e
d
ar
ti
cl
e
o
r
a
w
ri
tt
e
n
st
u
d
y
re
p
o
rt
5
ye
ar
s
*
C
h
an
,
2
0
0
4
a3
[1
8
]
Jo
u
rn
al
ar
ti
cl
e
4
ye
ar
s
3
1
(2
2
,4
0
)
1
(0
,
3
)
9
7
(9
1
,
1
0
0
)
C
h
an
,
2
0
0
4
b
3
[1
7
]
Jo
u
rn
al
ar
ti
cl
e
8
ye
ar
s
5
6
(5
0
,
6
2
)
2
(0
,
5
)
9
9
(9
7
,
1
0
0
)
G
h
e
rs
i,
2
0
0
6
[2
5
]
N
I
N
I
N
I
V
o
n
El
m
,
2
0
0
8
[2
9
]
Jo
u
rn
al
ar
ti
cl
e
8
ye
ar
s
*
T
u
re
r
2
0
0
7
[2
8
]
P
e
e
r
re
vi
e
w
e
d
jo
u
rn
al
ar
ti
cl
e
s
7
ye
ar
s
2
6
(2
0
,3
3
)4
*
*
D
e
jo
n
g
2
0
1
0
[2
1
]
A
n
o
ri
g
in
al
ar
ti
cl
e
co
n
ta
in
in
g
st
u
d
y
re
su
lt
s,
in
d
e
xe
d
in
M
ED
LI
N
E,
EM
B
A
SE
,
P
sy
ch
IN
FO
,
o
r
th
e
C
o
ch
ra
n
e
Li
b
ra
ry
6
m
o
n
th
s
to
9
ye
ar
s
N
I
B
lu
m
le
2
0
0
8
[3
1
]
A
rt
ic
le
s
p
u
b
lis
h
e
d
in
sc
ie
n
ti
fi
c
jo
u
rn
al
s
th
at
p
ro
vi
d
e
ad
e
q
u
at
e
in
fo
rm
at
io
n
o
n
at
le
as
t
th
e
o
b
je
ct
iv
e
s
o
f
th
e
st
u
d
y
as
w
e
ll
as
o
n
it
s
m
e
th
o
d
s
an
d
re
su
lt
s
7
ye
ar
s
*
H
al
l
2
0
0
7
[3
2
]
P
e
e
r
re
vi
e
w
e
d
jo
u
rn
al
1
0
–
1
1
ye
ar
s
N
I
1
D
e
n
o
m
in
at
o
r
is
th
e
to
ta
l
n
u
m
b
e
r
o
f
st
u
d
ie
s
w
it
h
kn
o
w
n
p
u
b
lic
at
io
n
st
at
u
s
in
th
e
co
h
o
rt
i.e
.
p
u
b
lis
h
e
d
p
lu
s
u
n
p
u
b
lis
h
e
d
p
lu
s
in
p
re
p
ar
at
io
n
p
lu
s
in
p
re
ss
.
2
D
e
n
o
m
in
at
o
r
is
th
e
n
u
m
b
e
r
su
b
m
it
te
d
.
3
D
e
n
o
m
in
at
o
r
in
cl
u
d
e
s
o
n
g
o
in
g
st
u
d
ie
s.
4
T
h
is
is
th
e
n
u
m
b
e
r
n
e
ve
r
p
re
se
n
te
d
an
d
w
e
h
av
e
as
su
m
e
d
n
o
t
su
b
m
it
te
d
.
*Q
u
e
st
io
n
n
o
t
as
ke
d
.
N
I
N
o
in
fo
rm
at
io
n
av
ai
la
b
le
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
6
8
4
4
.t
0
0
4
Study Publication Bias and Outcome Reporting Bias
PLOS ONE | www.plosone.org 32 July 2013 | Volume 8 | Issue 7 | e66844
T
a
b
le
5
.
C
o
m
p
ar
is
o
n
s
o
f
p
ri
m
ar
y
o
u
tc
o
m
e
st
at
e
d
in
p
ro
to
co
l
an
d
in
p
u
b
lic
at
io
n
.
S
tu
d
y
S
tu
d
y
le
v
e
l
O
u
tc
o
m
e
le
v
e
l
A
re
st
u
d
ie
s
w
it
h
st
a
ti
st
ic
a
ll
y
si
g
n
if
ic
a
n
t
o
r
p
o
si
ti
v
e
re
su
lt
s,
m
o
re
li
k
e
ly
to
b
e
p
u
b
li
sh
e
d
th
a
n
th
o
se
fi
n
d
in
g
n
o
d
if
fe
re
n
ce
b
e
tw
e
e
n
th
e
st
u
d
y
g
ro
u
p
?
P
ri
m
a
ry
o
u
tc
o
m
e
st
a
te
d
in
p
ro
to
co
l
is
th
e
sa
m
e
a
s
in
th
e
p
u
b
li
ca
ti
o
n
P
ri
m
a
ry
o
u
tc
o
m
e
st
a
te
d
in
p
ro
to
co
l
is
d
o
w
n
g
ra
d
e
d
to
se
co
n
d
a
ry
in
th
e
p
u
b
li
ca
ti
o
n
P
ri
m
a
ry
o
u
tc
o
m
e
st
a
te
d
in
th
e
p
ro
to
co
l
is
o
m
it
te
d
fr
o
m
th
e
p
u
b
li
ca
ti
o
n
A
n
o
n
p
ri
m
a
ry
o
u
tc
o
m
e
in
th
e
p
ro
to
co
l
is
ch
a
n
g
e
d
to
p
ri
m
a
ry
in
th
e
p
u
b
li
ca
ti
o
n
A
n
e
w
p
ri
m
a
ry
o
u
tc
o
m
e
th
a
t
w
a
s
n
o
t
st
a
te
d
in
th
e
p
ro
to
co
l
(a
s
p
ri
m
a
ry
o
r
se
co
n
d
a
ry
)
is
in
cl
u
d
e
d
in
th
e
p
u
b
li
ca
ti
o
n
T
h
e
d
e
fi
n
it
io
n
o
f
th
e
p
ri
m
a
ry
o
u
tc
o
m
e
w
a
s
d
if
fe
re
n
t
in
th
e
p
ro
to
co
l
co
m
p
a
re
d
to
th
e
p
u
b
li
ca
ti
o
n
C
o
m
p
le
te
n
e
ss
o
f
re
p
o
rt
in
g
O
v
e
ra
ll
D
e
fi
n
it
io
n
o
f
d
is
a
g
re
e
m
e
n
t/
d
is
cr
e
p
a
n
cy
Ea
st
er
b
ro
o
k,
19
91
[2
4]
O
R
2
.3
2
,
9
5
%
C
I;
1
.2
5
,
4
.2
8
.
*
*
*
*
*
*
*
*
*
D
ic
ke
rs
in
,
1
9
9
2
[2
3
]
O
R
2
.5
4
,
9
5
%
C
I;
1
.6
3
,
3
.9
4
*
*
*
*
*
*
*
*
*
D
ic
ke
rs
in
,
1
9
9
3
[3
]
O
R
1
2
.3
0
,
9
5
%
C
I;
2
.5
4
,
6
0
*
*
*
*
*
*
*
*
*
St
e
rn
,
1
9
9
7
[4
]
H
R
2
.3
2
,
9
5
%
C
I;
1
.4
7
,
3
.6
6
,
p
=
0
.0
0
0
3
*
*
*
*
*
*
*
*
*
C
o
o
p
e
r,
1
9
9
7
[1
9
]
p
,
0
.0
0
0
1
(s
u
b
m
is
si
o
n
o
n
ly
)
*
*
*
*
*
*
*
*
*
W
o
rm
al
d
,
1
9
9
7
[3
0
]
R
R
4
,
9
5
%
C
I;
0
.6
,
3
2
,
p
=
0
.1
0
*
*
*
*
*
*
*
*
*
Io
an
n
id
is
,
1
9
9
8
[5
]
*
*
*
*
*
*
*
*
*
*
P
ic
h
,
2
0
0
3
[2
7
]
*
*
*
*
*
*
*
*
*
*
C
ro
n
in
,
2
0
0
4
[2
0
]
O
R
0
.5
3
,
9
5
%
C
I;
0
.2
5
,
1
.1
p
=
0
.1
*
*
*
*
*
*
*
*
*
D
e
cu
lli
e
r,
2
0
0
5
2
[7
]
O
R
4
.5
9
,
9
5
%
C
I;
2
.2
1
,
9
.5
4
*
*
*
*
*
*
*
*
*
D
e
cu
lli
e
r,
2
0
0
6
[2
2
]
O
R
1
.5
8
,
9
5
%
C
I;
0
.3
7
,
6
.7
1
*
*
*
*
*
*
*
*
*
H
ah
n
,
2
0
0
2
[2
6
]
*
4
0
%
(6
/1
5
)
st
at
e
d
w
h
ic
h
o
u
tc
o
m
e
va
ri
ab
le
s
w
e
re
o
f
p
ri
m
ar
y
in
te
re
st
an
d
4
o
f
th
e
se
(6
7
%
)
sh
o
w
e
d
co
n
si
st
e
n
cy
in
th
e
re
p
o
rt
s
*
1
7
%
(1
/6
)
*
1
7
%
(1
/6
)
*
*
*
N
A
C
h
an
,
2
0
0
4
a1
[1
8
]
*
6
7
%
(3
2
/4
8
)
2
3
%
(1
1
/4
8
)
1
3
%
(6
/4
8
)
9
%
(4
/4
5
)
1
8
%
(8
/4
5
)
36
tr
ia
ls
re
p
o
rt
ed
a
p
o
w
er
ca
lc
u
la
ti
o
n
b
as
ed
o
n
a
p
ar
ti
cu
la
r
o
u
tc
o
m
e
in
th
ei
r
p
u
b
lic
at
io
n
s;
2
u
se
d
an
o
u
tc
o
m
e
th
at
d
iff
er
ed
fr
o
m
th
e
o
n
e
u
se
d
in
th
e
p
ro
to
co
l
an
d
an
o
th
er
in
tr
o
d
u
ce
d
a
p
o
w
er
ca
lc
u
la
ti
o
n
th
at
h
ad
n
o
t
b
ee
n
m
en
ti
o
n
ed
in
th
e
p
ro
to
co
l
P
ri
m
ar
y
o
u
tc
o
m
es
w
er
e
in
co
m
p
le
te
ly
re
p
o
rt
ed
in
7
(1
6%
)
o
f
45
tr
ia
ls
th
at
d
ef
in
ed
su
ch
o
u
tc
o
m
es
in
th
ei
r
p
u
b
lic
at
io
n
s
40
%
(1
9/
48
)
o
f
th
e
tr
ia
ls
co
n
ta
in
ed
m
aj
o
r
d
is
cr
ep
an
-
ci
es
in
th
e
sp
ec
ifi
ca
ti
o
n
o
f
p
ri
m
ar
y
o
u
tc
o
m
es
b
et
w
ee
n
th
e
p
ro
to
co
ls
an
d
p
u
b
lic
at
io
n
s.
N
o
n
e
o
f
th
e
p
u
b
lic
at
io
n
s
st
at
ed
th
at
an
am
en
d
m
en
t
h
ad
b
ee
n
m
ad
e
to
th
e
p
ro
to
co
l.
Th
e
fa
ilu
re
to
re
p
o
rt
a
p
re
-s
p
ec
ifi
ed
p
ri
m
ar
y
o
u
tc
o
m
e;
re
p
o
rt
in
g
o
f
a
p
re
sp
ec
ifi
ed
p
ri
m
ar
y
o
u
tc
o
m
e
as
se
co
n
d
ar
y
o
r
as
n
ei
th
er
p
ri
m
ar
y
n
o
r
se
co
n
d
ar
y
in
th
e
p
u
b
lic
at
io
n
;t
h
e
in
tr
o
d
u
ct
io
n
o
f
n
ew
p
ri
m
ar
y
o
u
tc
o
m
es
in
th
e
p
u
b
lic
at
io
n
;a
n
d
ch
an
g
in
g
th
e
o
u
tc
o
m
e
sp
ec
ifi
ed
fo
r
th
e
p
o
w
er
ca
lc
u
la
ti
o
n
.
Study Publication Bias and Outcome Reporting Bias
PLOS ONE | www.plosone.org 33 July 2013 | Volume 8 | Issue 7 | e66844
T
a
b
le
5
.
C
o
n
t.
S
tu
d
y
S
tu
d
y
le
v
e
l
O
u
tc
o
m
e
le
v
e
l
A
re
st
u
d
ie
s
w
it
h
st
a
ti
st
ic
a
ll
y
si
g
n
if
ic
a
n
t
o
r
p
o
si
ti
v
e
re
su
lt
s,
m
o
re
li
k
e
ly
to
b
e
p
u
b
li
sh
e
d
th
a
n
th
o
se
fi
n
d
in
g
n
o
d
if
fe
re
n
ce
b
e
tw
e
e
n
th
e
st
u
d
y
g
ro
u
p
?
P
ri
m
a
ry
o
u
tc
o
m
e
st
a
te
d
in
p
ro
to
co
l
is
th
e
sa
m
e
a
s
in
th
e
p
u
b
li
ca
ti
o
n
P
ri
m
a
ry
o
u
tc
o
m
e
st
a
te
d
in
p
ro
to
co
l
is
d
o
w
n
g
ra
d
e
d
to
se
co
n
d
a
ry
in
th
e
p
u
b
li
ca
ti
o
n
P
ri
m
a
ry
o
u
tc
o
m
e
st
a
te
d
in
th
e
p
ro
to
co
l
is
o
m
it
te
d
fr
o
m
th
e
p
u
b
li
ca
ti
o
n
A
n
o
n
p
ri
m
a
ry
o
u
tc
o
m
e
in
th
e
p
ro
to
co
l
is
ch
a
n
g
e
d
to
p
ri
m
a
ry
in
th
e
p
u
b
li
ca
ti
o
n
A
n
e
w
p
ri
m
a
ry
o
u
tc
o
m
e
th
a
t
w
a
s
n
o
t
st
a
te
d
in
th
e
p
ro
to
co
l
(a
s
p
ri
m
a
ry
o
r
se
co
n
d
a
ry
)
is
in
cl
u
d
e
d
in
th
e
p
u
b
li
ca
ti
o
n
T
h
e
d
e
fi
n
it
io
n
o
f
th
e
p
ri
m
a
ry
o
u
tc
o
m
e
w
a
s
d
if
fe
re
n
t
in
th
e
p
ro
to
co
l
co
m
p
a
re
d
to
th
e
p
u
b
li
ca
ti
o
n
C
o
m
p
le
te
n
e
ss
o
f
re
p
o
rt
in
g
O
v
e
ra
ll
D
e
fi
n
it
io
n
o
f
d
is
a
g
re
e
m
e
n
t/
d
is
cr
e
p
a
n
cy
C
h
an
,
2
0
0
4
b
1
[1
7
]
*
4
7
%
(3
6
/7
6
)
3
4
%
(2
6
/7
6
)
2
6
%
(2
0
/7
6
)
1
9
%
(1
2
/6
3
)
1
7
%
(1
1
/6
3
)
3
8
tr
ia
ls
re
p
o
rt
e
d
a
p
o
w
e
r
ca
lc
u
la
ti
o
n
,
b
u
t
4
ca
lc
u
la
ti
o
n
s
w
e
re
b
as
e
d
o
n
an
o
u
tc
o
m
e
o
th
e
r
th
an
th
e
o
n
e
u
se
d
in
th
e
p
ro
to
co
l.
In
an
o
th
e
r
6
ca
se
s,
th
e
re
w
as
a
p
o
w
e
r
ca
lc
u
la
ti
o
n
p
re
se
n
te
d
in
a
p
u
b
lis
h
e
d
ar
ti
cl
e
b
u
t
n
o
t
in
th
e
p
ro
to
co
l
P
ri
m
ar
y
o
u
tc
o
m
e
s
w
e
re
sp
e
ci
fi
e
d
fo
r
6
3
o
f
th
e
p
u
b
lis
h
e
d
tr
ia
ls
,
b
u
t
fo
r
1
7
(2
7
%
)
o
f
th
e
se
tr
ia
ls
at
le
as
t
o
n
e
p
ri
m
ar
y
o
u
tc
o
m
e
w
as
in
co
m
p
le
te
ly
re
p
o
rt
e
d
.
6
2
%
(5
1
/8
2
)
o
f
tr
ia
ls
h
ad
m
aj
o
r
d
is
cr
e
p
an
ci
e
s
b
e
tw
e
e
n
p
ri
m
ar
y
o
u
tc
o
m
e
s
sp
e
ci
fi
e
d
in
p
ro
to
co
ls
an
d
th
o
se
d
e
fi
n
e
d
in
th
e
p
u
b
lis
h
e
d
ar
ti
cl
e
s
(a
t
le
as
t
1
p
ri
m
ar
y
o
u
tc
o
m
e
th
at
w
as
ch
an
g
e
d
,
in
tr
o
d
u
ce
d
o
r
o
m
it
te
d
).
A
p
re
sp
e
ci
fi
e
d
p
ri
m
ar
y
o
u
tc
o
m
e
w
as
re
p
o
rt
e
d
as
se
co
n
d
ar
y
o
r
w
as
n
o
t
la
b
e
lle
d
as
e
it
h
e
r;
a
p
re
sp
e
ci
fi
e
d
p
ri
m
ar
y
o
u
tc
o
m
e
w
as
o
m
it
te
d
fr
o
m
th
e
p
u
b
lis
h
e
d
ar
ti
cl
e
s;
a
n
e
w
p
ri
m
ar
y
o
u
tc
o
m
e
w
as
in
tr
o
d
u
ce
d
in
th
e
p
u
b
lis
h
e
d
ar
ti
cl
e
s
an
d
th
e
o
u
tc
o
m
e
u
se
d
in
th
e
p
o
w
e
r
ca
lc
u
la
ti
o
n
w
as
n
o
t
th
e
sa
m
e
in
th
e
p
ro
to
co
l
an
d
th
e
p
u
b
lis
h
e
d
ar
ti
cl
e
s.
G
h
e
rs
i,
2
0
0
6
[2
5
]
*
7
4
%
*
3
1
%
*
1
0
%
6
0
%
d
e
fi
n
it
io
n
th
e
sa
m
e
,
3
1
%
u
n
ab
le
to
ju
d
g
e
an
d
8
%
d
is
cr
e
p
an
t
T
h
e
o
d
d
s
o
f
fu
lly
re
p
o
rt
in
g
a
co
m
p
ar
is
o
n
w
e
re
g
re
at
e
r
if
th
e
re
su
lt
w
as
st
at
is
ti
ca
lly
si
g
n
if
ic
an
t,
(O
R
2
.2
,
9
5
%
C
I;
0
.9
–
5
.3
,
p
=
0
.0
8
)
*
N
A
V
o
n
El
m
,
2
0
0
8
[2
9
]
*
*
*
2
6
%
(2
4
/9
2
)
*
1
1
%
(1
1
/1
0
1
)
*
*
*
N
A
T
u
re
r
2
0
0
7
[2
8
]
*
*
*
*
*
*
*
*
*
*
D
e
jo
n
g
2
0
1
0
[2
1
]
*
*
*
*
*
*
*
*
*
*
B
lu
m
le
2
0
0
8
[3
1
]
*
*
*
*
*
*
*
*
*
*
H
al
l
2
0
0
7
[3
2
]
*
*
*
*
*
*
*
*
*
*
N
A
N
o
t
A
p
p
lic
ab
le
.
*T
h
e
st
u
d
y
d
id
n
o
t
in
ve
st
ig
at
e
th
is
.
1
G
iv
e
s
re
su
lt
s
fo
r
tr
ia
ls
w
it
h
d
is
cr
e
p
an
ci
e
s
fo
r
$
1
p
ri
m
ar
y
o
u
tc
o
m
e
.
2
R
e
su
lt
s
o
b
ta
in
e
d
fr
o
m
2
4
8
o
f
th
e
co
m
p
le
te
d
st
u
d
ie
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
6
6
8
4
4
.t
0
0
5
Study Publication Bias and Outcome Reporting Bias
PLOS ONE | www.plosone.org 34 July 2013 | Volume 8 | Issue 7 | e66844
In this review we focused on empirical studies that included
RCTs since they provide the best evidence of the efficacy of
medical interventions [60]. RCTs are prone to study publication
bias, but it has been shown that other types of studies are more
prone to study publication bias [24]. The main limitation of this
review was that for eleven of the 20 included cohorts, information
on RCTs could not be separated from information on other
studies. Due to this barrier, and variability across empirical studies
in the time lapse between when the protocol was approved and
when the data were censored for analysis, we felt it was not
appropriate to combine statistically the results from the different
cohorts. Also, the fact that in six empirical studies [3,4,7,21,22,24]
follow-up of trials was less than 90% could mean that the problem
of study publication bias is underestimated in these cohorts.
It is difficult to tell the current state of the literature with respect
to study publication bias, as even the most recently published
empirical evaluations included in the review, considered RCTs
which began 10 years ago. Nevertheless, the empirical studies that
were published within the last ten years show that the total amount
of studies published was less than 50% on average.
None of the empirical studies explored the idea of all outcomes
being non-significant versus those deemed most important being
non-significant. In the reasons given, it was not stated which
outcomes/how many outcomes were non-significant. Some
empirical studies imply that all results were non-significant
although this is due to the way the reason was written i.e. no
significant results; but it is not explained whether this means for all
outcomes, or primary and secondary, harm and efficacy etc. This
implies a potential ambiguity of ‘no significant results’. It is not
clear whether studies remain unpublished because all outcomes
are non-significant and those that are published are so because
significant results are selectively reported. This is where study
publication bias and outcome reporting bias overlap.
Dubben et al [61] looked at whether study publication bias
exists in studies which investigate the problem of study publication
bias. Although they found no evidence of study publication bias, it
is interesting to note that two of the included cohorts in this review
have not been published [25,30]. The study conducted by
Wormald et al [30] concluded that ‘there was limited evidence
of study publication bias’ whereas the authors of the other study
[25] have not submitted their study for publication. There may be
other unpublished studies of study publication bias or outcome
reporting bias that were not located by the search, however
contact with experts in the field reduces the likelihood of these
issues introducing bias.
Submission is an important aspect of investigating study
publication bias as it will provide information on whether reports
are not being published because they are not submitted or they are
submitted but not accepted. Obviously those studies that are not
submitted are not published and it was found by Dickersin et al
[62] that non-publication was primarily a result of failure to write
up and submit the trial results rather than rejection of submitted
manuscripts. This is confirmed for the cohorts identified here with
the percentage of studies not published due to not being submitted
ranging from 63% to 100%. Olson et al [63] also found that there
was no evidence that study publication bias occurred once
manuscripts had been submitted to a medical journal. However,
this study looks at a high impact general journal, which is unlikely
to be representative for specialist journals that publish the majority
of clinical trials.
Eleven studies assessed the impact of funding on publication;
this was done in several ways. Three studies found that external
funding lead to a higher rate of publication [4,22,23]. von Elm
et al [29] found that the probability of publication decreased if the
study was commercially funded and increased with non commer-
cial funding. Easterbrook et al [24] found that compared with
unfunded studies, government funded studies were more likely to
yield statistically significant results but government sponsorship
was not found to have a statistically significant effect on the
likelihood of publication and company sponsored trials were less
likely to be published or presented. Dickersin et al [3] found no
difference in the funding mechanism grant versus contract and
Ioannidis et al [5] found no difference in whether data were
managed by the pharmaceutical industry or other federally
sponsored organisations. Chan 2004b et al [17] found that 61%
of the 51 trials with major discrepancies were funded solely by
industry sources compared with 49% of the 51 trials without
discrepancies. Ghersi [25] did examine the effect of funding in
terms of reporting and discrepancies of outcomes but no
information about the results is currently available. Hahn et al
[26] compared the funder stated in protocol to publication. Hall
et al [32] found that studies sponsored by the pharmaceutical
industry were less likely to be published than those sponsored by
federal granting agencies (RR 0.50; 95% CI 0.39–0.65;
P= 0.0045) but were more likely to be published than studies
funded by the local health authority (RR 1.94; 95% CI 1.09–3.44;
P= 0.011). These studies indicate that funding is an important
factor to consider when investigating publication bias and outcome
reporting bias, however more work needs to be done to examine
common questions before conclusions regarding the relationship
between funding and outcome reporting bias can be drawn.
Our review has examined inception cohorts only, however,
other authors have investigated aspects of study publication bias
and outcome reporting bias using different study designs, with
similar conclusions. Since the original version of this review was
published [13], a Cochrane methodology review is now available
on publication bias [64]. This review included five studies, only
one of which was not included in our review as it was not an
inception cohort [40]. Hopewell et al concluded that trials with
positive findings are published more often and more quickly than
trials with negative findings [64]. The Cochrane review by Scherer
et al [6] investigating the full publication of results initially
presented in abstracts found that only 63% of results from
abstracts describing randomized or controlled clinical trials are
published in full and ’positive’ results were more frequently
published than non ’positive’ results. Several studies investigated a
cohort of trials submitted to drug licensing authorities
[38,40,41,65] and all found that many of these trials remain
unpublished, with one study demonstrating that trials with positive
outcomes resulted more often in submission of a final report to the
regulatory authority [40]. Olson et al [63] conducted a prospective
cohort study of manuscripts submitted to JAMA and assessed
whether the submitted manuscripts were more likely to be
published if they reported positive results. They did not find a
statistically significant difference in publication rates between those
with positive and negative results. None of the inception cohorts
addressed the question as to whether the significance determined
whether a submitted paper was accepted or not, with the
exception of one inception cohort [5] that found that ‘‘positive’’
trials were published significantly more rapidly after submission
than ‘‘negative’’ trials. Finally, a comparison of the published
version of RCTs in a specialist clinical journal with the original
trial protocol found that important changes between protocol and
published paper are common; the published primary outcome was
exactly the same as in the protocol in six out of 26 trials (23%) [50]
This was also highlighted in a recent Cochrane methodological
review [16], which included 12 studies comparing protocols to
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published reports and four studies comparing trial registry entries
to published reports.
We recommend that researchers use the flow diagram presented
in this work as the standard for reporting of future similar studies
that look at study publication bias and ORB as it clearly shows
what happens to all trials in the cohort.
Reviewers should scrutinise trials with missing outcome data
and ensure that an attempt to contact trialists is always made if the
study does not report results. An outcome matrix generator has
now been developed as a tool to help identify missing outcome
data at the study level within a review (http://ctrc.liv.ac.uk/orbit/
). Also, the lack of reporting of specified outcome(s) should not be
an automatic reason for exclusion of studies. Statisticians should be
involved for the data extraction of more complex outcomes, for
example, time to event. Methods that have been developed to
assess the robustness of the conclusions of systematic reviews to
ORB [66–68] should be used. Meta-analyses of outcomes where
several relevant trials have missing data should be seen with extra
caution. In all, the credibility of clinical research findings may
decrease when there is wide flexibility in the use of various
outcomes and analysis in a specific field and this is coupled with
selective reporting biases.
The setting up of clinical trials registers and the advanced
publication of detailed protocols with an explicit description of
outcomes and analysis plans should help combat these problems,
although it should be noted that other work has shown that there
can be discrepancies between protocols/trial registries and
published reports [16]. Trialists should be encouraged to describe
legitimate changes to outcomes stated in the protocol.
For empirical evaluations of selective reporting biases, the
definition of significance is important as is whether the direction of
the results is taken into account, i.e. whether the results are
significant for or against the experimental intervention. However,
only one study took this into account [5]. The selective publication
preference forces may change over time. For example, it is often
seen that initially studies favouring treatment are more likely to be
published and those favouring control suppressed. However, as
time passes, contradicting trials that favour control may become
attractive for publication, as they are ‘different.’ The majority of
cohorts included in this review do not consider this possibility.
Another recommendation is to conduct empirical evaluations
looking at both ORB and study publication bias in RCTs to
investigate the relative importance of both i.e. which type of bias is
the greater problem. The effects of factors such as funding, i.e. the
influence of pharmaceutical industry trials versus non pharma-
ceutical trials, should also be factored in these empirical
evaluations.
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